Histone acetylation in gene regulation

Briefings in Functional Genomics and Proteomics

Volumn 5, Issue 3, 2006, Pages 209-221

  Verdone, Loredana ^b   Agricola, Eleonora ^b   Caserta, Micaela ^b   Di Mauro, Ernesto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

Acetylation; Cancer; Deacetylation; Gene expression; Nucleosomes

Indexed keywords

HISTONE; LYSINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE;

ACETYLATION; AMINO TERMINAL SEQUENCE; CHROMATIN; DNA PACKAGING; EUKARYOTIC CELL; GENE CONTROL; HUMAN; NONHUMAN; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

EUKARYOTA;

ACETYLATION; ANIMALS; CHROMATIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 33845198169     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/ell028     Document Type: Review

References (161)

1. Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60.
2. Parseghian MH, Newcomb RL, Winokur ST, et al. The distribution of somatic H1 subtypes is non-random on active vs. inactive chromatin: distribution in human fetal fibroblasts. Chromosome Res 2000;8:405-24.
3. Henikoff S, Ahmad K, Platero JS, et al. Heterochromatic deposition of centromeric histone H3-like proteins. Proc Natl Acad Sci USA 2000;97:716-21.
4. Meluh PB, Yang P, Glowczewski L, et al. Cse4p is a component of the core centromere of Saccharomyces cerevisiae. Cell 1998;94:607-13.
5. Clarkson MJ, Wells JR, Gibson F, et al. Regions of variant histone His2AvD required for Drosophila development. Nature 1999;399:694-7.
6. Leach TJ, Mazzeo M, Chotkowski HL, et al. Histone H2A.Z is widely but nonrandomly distributed in chromosomes of Drosophila melanogaster. J Biol Chem 2000;275:23267-72.
7. Dhillon N, Kamakaka RT. Breaking through to the other side: Silencers and barriers. Curr Opin Genet Dev 2002;12: 188-92.
8. Adam M, Robert F, Larochelle M, et al. H2A.Z is required for global chromatin integrity and for recruitment of RNA polymerase II under specific conditions. Mol Cell Biol 2001; 21:6270-9.
9. Dhillon N, Oki M, Szyjka SJ, et al. H2A.Z functions to regulate progression through the cell cycle. Mol Cell Biol 2006;26:489-501.
10. Guillemette B, Bataille AR, Gevry N, et al. Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning. PLoS Biol 2005;3:2100-10.
11. Zhang H, Roberts DN, Cairns BR. Genome-wide dynamics of HTZ1, a histone H2A variant that poises repressed/basal promoters for activation through histone loss. Cell 2005;123:219-231.
12. Raisner RM, Hartley PD, Meneghini MD, et al. Histone variant H2A.Z marks the 5′ ends of both active and inactive genes in euchromatin. Cell 2005;123:233-48.
13. Li B, Pattenden SG, Lee D, et al. Preferential occupancy of histone variant H2A.Z at inactive promoters influences local histone modifications and chromatin remodeling. Proc Natl Acad Sci USA 2005;102:18385-90.
14. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
15. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002;12:142-8.
16. Turner BM. Cellular memory and the histone code. Cell 2002;111:285-91.
17. Fischle W, Wang Y, Allis CD. Binary switches and modification cassettes in histone biology and beyond. Nature 2003;425:475-9.
18. Brownell JE, Zhou J, Ranalli T, et al. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996;84: 843-51.
19. Allfrey Vg, Faulkner R, Mirsky Ae. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc Natl Acad Sci USA 1964;51: 786-94.
20. Marmorstein R. Protein modules that manipulate histone tails for chromatin regulation. Nat Rev Mol Cell Biol 2001;2: 422-32.
21. Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003;4:276-84.
22. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-94.
23. Yang XJ. Lysine acetylation and bromodomain: A new partnership for signaling. Bioessays 2004;26:1076-87.
24. Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399:491-6.
25. Hassan AH, Prochasson P, Neely KE, et al. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 2002;111:369-79.
26. Mujtaba S, He Y, Zeng L, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004;13:251-63.
27. Jacobson RH, Ladurner AG, King DS, et al. Structure and function of a human TAFII250 double bromodomain module. Science 2000;288:1422-5.
28. Vogelauer M, Wu J, Suka N, et al. Global histone acetylation and deacetylation in yeast. Nature 2000;408: 495-8.
29. Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell 2004; 117:721-33.
30. Dion MF, Altschuler SJ, Wu LF, et al. Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci USA 2005;102:5501-6.
31. Pokholok DK, Harbison CT, Levine S, et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 2005;122:517-27.
32. Schubeler D, Turner BM. A new map for navigating the yeast epigenome. Cell 2005;122:489-92.
33. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003;13:172-83.
34. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14:546-51.
35. Candau R, Moore PA, Wang L, et al. Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5. Mol Cell Biol 1996;16: 593-602.
36. Xu W, Edmondson DG, Roth SY. Mammalian GCN5 and P/CAF acetyltransferases have homologous amino-terminal domains important for recognition of nucleosomal substrates. Mol Cell Biol 1998;18:5659-69.
37. Georgakopoulos T, Thireos G. Two distinct yeast transcriptional activators require the function of the GCN5 protein to promote normal levels of transcription. EMBO J 1992;11:4145-52.
38. Kleff S, Andrulis ED, Anderson CW, et al. Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem 1995;270:24674-7.
39. Smith ER, Belote JM, Schiltz RL, et al. Cloning of Drosophila GCN5: conserved futures among metazoan GCN5 funily members. Nucleic Acids Res 1998; 26:2948-54.
40. Hettmann C, Soldati D. Cloning and analysis of a Toxoplasma gondii histone acetyltransferase: A novel chromatin remodelling factor in apicomplexan parasites. Nucleic Acids Res 1999;27:4344-52.
41. Puri PL, Sartorelli V, Yang XJ, et al. Differential roles of p300 and PCAF acetylatransferases in muscle differentiation. Mol Cell 1997;1:35-45.
42. Blanco JC, Minucci S, Lu J, et al. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 1998;12: 1638-51.
43. Korzus E, Torchia J, Rose DW, et al. Transcription factor-specif requirements for co-activators and their acetyltransferase function. Science 1998;279:703-7.
44. Xu L, Lavinsky RM, Dasen JS, et al. Signal-specific co-activator domain requirements for Pit-1 activation. Nature 1998;395:301-6.
45. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996;384:641-3.
46. Shikama N, Lyon J, La Thangue NB. The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends Cell Biol 1997;6:230-6.
47. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000;64: 435-59.
48. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41.
49. Parthun MR, Widom J, Gottschling DE. The major cytoplasmic histone acetyltransferase in yeast: Links to chromatin replication and histone metabolism. Cell 1996; 87:85-94.
50. Ruiz-Garcia AB, Sendra R, Galiana M, et al. HAT1 and HAT2 proteins are components of a yeast nuclear histone acetyltransferase enzyme specific for free histone H4. J Biol Chem 1998;273:12599-605.
51. Qin S, Parthun MR. Recruitment of the type B histone acetyltransferase Hat1p to chromatin is linked to DNA double-strand breaks. Mol Cell Biol 2006;26: 3649-58.
52. Wittschieben B, Otero G, de Bizemont T, et al. A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. Mol Cell 1999;4:123-8.
53. Kristjuhan A, Walker J, Suka N, et al. Transcriptional inhibition of genes with severe histone H3 hypoacetylation in the coding region. Mol Cell 2002;10:925-33.
54. Otero G, Fellows J, Li T, et al. Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol Cell 1999;3:109-18.
55. Borrow J, Stanton VP, Andersen JM, Jr, et al. The translocation t(8;16) (p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14:33-41.
56. Carapeti M, Aguiar RC, Goldman JM, et al. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemias. Blood 1998; 91:3127-33.
57. Liang J, Prouty L, Williams BJ, et al. Acute mixed lineage leukemia with an inv(8) (p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 1998;92:2118-22.
58. Rozman M, Camos M, Colomer D, et al. Type MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16) (p11;p13) translocation. Genes Chromosomes Cancer 2004;40:140-5.
59. Kim MS, Merlo X, Wilson C, et al. Co-activation of atrial natriuretic factor promoter by Tip60 and serum response factor. J Biol Cell 2006 Apr 5, in press.
60. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acid Res 2004;32:959-76.
61. Kusch T, Florens L, Macdonald WH et al. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. Science 2004;306:2084-7.
62. Champagne N, Bertos NR, Pelletier N, et al. Identification of a human histone acetyltransferase related to monocyte leukemia zinc finger protein. J Biol Chem 1999;274: 28528-36.
63. Burke TW, Cook JG, Nevins JR. Replication factors MCM2 and ORC1 interact with the histone acetyltransferase HBO1. J Biol Chem 2001;276:15397-408.
64. Iizuka M, Stillman B. Histone acetyltransferase HBO1 interacs with ORC1 subunit of the human initiator protein. J Biol Chem 1999;274:23027-34.
65. Berger SL, Pina B, Silverman N, et al. Genetic isolation of ADA2: A potential transcriptional adaptor required for function of certain acidic activation domains. Cell 1992;70: 251-65.
66. Holstege FC, Jennings EG, Wyrick JJ, et al. Dissecting the regulatory circuitry of a eukaryotic genome. Cell 1998;95: 717-28.
67. Zhang W, Bone JR, Edmondson DG, et al. Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J 1998;17:3155-67.
68. Suka N, Suka Y, Carmen AA, et al. Highly specific antibodies determine histone acetylation site usage in yeast heterochromatin and euchromatin. Mol Cell 2001;8:473-9.
69. Grant PA, Duggan L, Cote J, et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 1997;11:1640-50.
70. Brown CE, Lechner T, Howe L, et al. The many HATs of transcription co-activators. Trends Biochem Sci 2000;25:15-9.
71. Eberharter A, Sterner DE, Schieltz D, et al. The ADA complex is a distinct histone acetyltransferase complex in Saccharomyces cerevisiae. Mol Cell Biol 1999;19:6621-31.
72. Grant PA, Workman JL. Transcription: A lesson in sharing? Nature 1998;396:410-1.
73. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120.
74. Waterborg JH. Steady-state levels of histone acetylation in Saccharomyces cereviasie. J Biol Chem 2000;275: 13007-11.
75. Imoberdorf RM, Topalidou I, Strubin M. A role for gcn5-mediated global histone acetylation in transcriptional regulation. Mol Cell Biol 2006;26:1610-6.
76. Deckert J, Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell 2001;21:2726-35.
77. Allard S, Utley RT, Savard J, et al. NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATF-related cofactor Tra1p. EMBO J 1999;18:5108-19.
78. Reid JL, Iyer VR, Brown PO, et al. Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. Mol Cell 2000;6: 1297-307.
79. Durant M, Pugh BF. Genome-wide relationships between TAF1 and histone acetyltransferases in Saccharomyces cerevisiae. Mol Cell Biol 2006;26:2791-802.
80. Mizzen CA, Yang XJ, Kobuko T, et al. The TAF(II)250 subunit of TAFIID has histone acetyltransferase activity. Cell 1996;87:1261-70.
81. Lee TI, Causton HC, Holstege FC, et al. Redundant roles for the TFIID and SAGA complexes in global transcription. Nature 2000;405:701-4.
82. Hilton TL, Li Y, Dunphy EL, et al. TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. Mol Cell Biol 2005;25:4321-32.
83. Matangkasombut O, Buratowski RM, Swilling NW, et al. Bromodomain factor 1 corresponds to a missing piece of yeast TFIID. Genes Dev 2000;14:951-62.
84. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005;83:344-53.
85. Robyr D, Suka Y, Xenarios I, et al. Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases Cell 2002;109:437-46.
86. Grozinger CM, Schreiber SL. Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem Biol 2002;9:3-16.
87. Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev 2004;31;1-17.
88. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19: 286-93.
89. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-48.
90. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59.
91. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005;41:2381-402.
92. Waterborg JH. Dynamics of histone acetylation in Saccharomyces cerevisiae. Biochemistry 2001;40:2599-605.
93. Katan-Khaykovich Y, Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: Rapid restoration of normal histone acetylation status upon removal of activators and repressors Genes Dev 2002;16:743-52.
94. Verdone L, Camilloni G, Di Mauro E, et al. Chromatin remodeling during saccharomyces cerevisiae ADH2 gene activation. Mol Cell Biol 1996;16:1978-88.
95. Verdone L, Wu J, van Riper K, et al. Hyperacetylation of chromatin at the ADH2 promoter allows Adr1 to bind in repressed conditions. EMBO J 2002;21:1101-11.
96. Agricola E, Verdone L, Xella B, et al. Common chromatin architecture, common chromatin remodeling, and common transcription kinetics of Adr1-dependent genes in Saccharomyces cerevisiae. Biochemisty 2004;43:8878-84.
97. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
98. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
99. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
100. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
101. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005;45: 629-56.
102. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
103. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modification and gene expression on DNA hypermethylation in cancer Cancer. Res 2002;62:7213-8.
104. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-45.
105. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14: 65-76.
106. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37: 391-400.
107. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6
108. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006;5:37-50.
109. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005;32:521-30.
110. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006; 94:179-83.
111. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2004;90:761-9.
112. Kang J, Chen J, Shi Y, et al. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol 2005;69:1205-13.
113. Panagopoulos I, Teixeira MR, Micci F, et al. Acute myeloid leukemia with inv(8)(p11q13). Leuk Lymphoma 2000;39:6516-6.
114. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 2004;6:587-96.
115. Murati A, Adelaide J, Popovici C, et al. A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. Int J Mol Med 2003;12:423-8.
116. Yao TP, Oh SP, Fuchs M, et al. Gene osage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300 Cell 1998;93:361-72.
117. Kung AL, Rebel VI, Bronson RT, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000;14:272-7.
118. Shigeno K, Yoshida H, Pan L, et al. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett 2004;213:11-20.
119. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24: 300-3.
120. Murata T, Kurokawa R, Krones A, et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome Hum Mol Genet 2001;10:1071-6.
121. Alarcon JM, Malleret G, Touzani K, et al. Chromatin acetylation memory and LTP are impaired in CBP+/-mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration Neuron. 2004;42: 947-59.
122. Korzus E, Rosenfeld MG, Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004;42:961-72.
123. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-31.
124. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14: 1553-77.
125. Zhang Q, Yao H, Vo N, et al. Acetylation of adenovirus E1A regulates binding of the transcriptional corepressor CtBP. Proc Natl Acad Sci USA 2000;97: 14323-8.
126. Patel JH, Du Y, Ard PG, et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004;24:10826-34.
127. Taubert S, Gorrini C, Frank SR, et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 2004;24:4546-56.
128. Urnov FD, Yee J, Sachs L, et al. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erb. A yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J 2000;19:4074-90.
129. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
130. Minucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999;10:215-25.
131. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000;5: 811-20.
132. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet 1999;15: 179-84.
133. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000;3:821-30.
134. Faretta M, Di Croce L, Pelicci PG. Effects of the acute myeloid leukemia-associated fusion proteins on nuclear architecture. Semin Hematol 2001;38:42-53.
135. Jones LK, Saba V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 2002;118:714-27.
136. Moe-Behrens GH Pandolfi PP. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol 2003;7:139-59.
137. Bowen NJ, Fujita N, Kajita M, et al. Mi-2/NuRD: Multiple complexes for many purposes. Biochim Biophys Acta 2004;1677:52-7.
138. Toh Y, Ohga T, Endo K, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 2004; 110:362-7.
139. Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 2006;12:1479-86.
140. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006; 23:1231-41.
141. Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;3:455-63.
142. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
143. Insinga A, Monestiroli S, Ronzoni S, et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004;23:1144-54.
144. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;23:261-309.
145. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23:138-49.
146. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102: 673-8.
147. Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101:1241-6.
148. Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
149. Roy S, Packman K, Jeffrey R, et al. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005;12:482-91.
150. Luo J, Su F, Chen D, et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408: 377-81.
151. Subramanian C, Opipari AW, Jr, Bian X, et al. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:4842-7.
152. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
153. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19: 1751-9.
154. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92: 1210-6.
155. Marks PA, Richon VM, Breswlow R. Histone deacetylases inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13:1-13.
156. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001;12: 294-300.
157. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002;13: 1-13.
158. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7.
159. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/ CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/non histone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279: 51163-71.
160. Aggarwal S, Ichikawa H, Takada Y, et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of Ikappa B alpha kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
161. Jones PA, Martienssen R. A blueprint for Human Epigenome Project: The AACR Human Epigenome Workshop. Cancer Res 2005;24:11241-6.